For their study, the researchers aimed to clarify the mechanisms behind racial and ethnic disparities in multiple myeloma disease outcomes by investigating the demographic, clinical, and molecular features...
The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
The ANDROMEDA study was a phase 3 trial comparing bortezomib, cyclophosphamide, and dexamethasone therapy with daratumumab as an add-on therapy in patients with light chain amyloidosis.
The ANDROMEDA study was a phase 3 trial comparing bortezomib, cyclophosphamide, and dexamethasone therapy with daratumumab as an add-on therapy in patients with light chain amyloidosis.
The APOLLO study was a phase 3 trial comparing pomalidomide and dexamethasone therapy with daratumumab as an add-on therapy in patients with relapsed or refractory multiple myeloma who were refractory to...
The APOLLO study was a phase 3 trial comparing pomalidomide and dexamethasone therapy with daratumumab as an add-on therapy in patients with relapsed or refractory multiple myeloma who were refractory to...
The researchers conducted 2 studies to test the oral, small-molecule, next-generation sickle hemoglobin inhibitor would safely and substantially reduce erythrocyte hemolysis and increase hemoglobin.
The researchers conducted 2 studies to test the oral, small-molecule, next-generation sickle hemoglobin inhibitor would safely and substantially reduce erythrocyte hemolysis and increase hemoglobin.
